Menin inhibitors reshape AML care, boosting targeted options for KMT2A- and NPM1-mutant disease, with promising frontline ...
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (NASDAQ: OMER) today announced the successful completion of its initial study in nonhuman primates evaluating the efficacy and safety of its OncotoX-AML ...
Supports capital-efficient expansion of the SLS009 clinical program into frontline AML, enabling broader U.S. and European patient enrollment U.S. enrollment evaluating SLS009 in combination with ...
Stocktwits on MSN
SLS stock pops after-hours as loss shrinks, cash swells — all eyes on high stakes AML trial in 'pivotal' 2026
Net loss in FY25 narrowed to $26.9 million from $30.9 million a year ago, with R&D costs falling to $16 million. ・Phase 3 ...
— OncotoX-AML Effectively Ablated Myeloid Progenitor Cells that Give Rise to AML in Cancer Patients — Omeros Corporation (NASDAQ: OMER) today announced the successful completion of its initial study ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results